Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents

Molecular Pharmacology

Volumn 69, Issue 4, 2006, Pages 1216-1225

  Kuryshev, Yuri A ^a   Wang, Lu ^a   Wible, Barbara A ^b   Wan, Xiaoping ^a   Ficker, Eckhard ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ChanTest Corporation   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; ANTIMONY TARTRATE; CALCIUM; MEGLUMINE ANTIMONATE; POTASSIUM CHANNEL HERG; SODIUM; STIBOGLUCONATE SODIUM;

ACTION POTENTIAL; ARTICLE; CALCIUM BLOOD LEVEL; CELL MATURATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERANCE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; LEISHMANIASIS; PRIORITY JOURNAL; QT PROLONGATION; TORSADE DES POINTES; WESTERN BLOTTING;

ACTION POTENTIALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CALCIUM; CELL LINE; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LEISHMANIASIS, VISCERAL; LONG QT SYNDROME; MYOCARDIUM; TORSADES DE POINTES;

EID: 33645098736     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.019281     Document Type: Article

References (41)

1. Alvarez M, Malecot CO, Gannier F, and Lignon JM (2005) Antimony-induced cardiomyopathy in guinea-pig and protection by L-carnitine. Br J Pharmacol 144:17-27.
2. Balser JR (2001) The cardiac sodium channel: gating function and molecular pharmacology. J Mol Cell Cardiol 33:599-613.
3. Berhe N, Abraham Y, Hailu A, Ali A, Mengistu G, Tsige K, and Abebe Y (2001) Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral Leishmaniasis. East Afr Med J 78:608-610.
4. Berman JD, Chulay JD, Hendricks LD, and Oster CN (1982) Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 31:459-465.
5. Berman JD and Wyler DJ (1980) An in vitro model for investigation of chemotherapeutic agents in Leishmaniasis. J Infect Dis 142:83-86.
6. Berube J, Caouette D, and Daleau P (2001) Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian cell line. J Pharmacol Exp Ther 297:96-102.
7. Burguera JL, Burguera M, Petit de Pena Y, Anez N, and Lugo de Yarbuh A (1993) Selective determination of antimony (III) and antimony (V) in serum and urine and total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimoniate. Trace Elem Med 10:66-70.
8. Cesur S, Bahar K, and Erekul S (2002) Death from cumulative sodium stibogluconate toxicity on Kala-Azar. Clin Microbiol Infect 8:606.
9. Chulay JD, Spencer HC, and Mugambi M (1985) Electrocardiographic changes during treatment of Leishmaniasis with pentavalent Antimony (sodium stibogluconate). Am J Trop Med Hyg 34:702-709.
10. Doenges J (1968) Therapie der Bilharziose. Dtsch Med Wochenschr 93:493-495.
11. European Medicines Agency (2004) ICH S7B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. European Medicines Agency EMEA, CHMP/ICH/423/02. (http://www.emea.eu.int/pdfs/human/ich/042302en.pdf).
12. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, and Cantilena LR (2004) Drug-induced Torsades de Pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495.
13. Ficker E, Dennis AT, Wang L, and Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92:e87-100.
14. Ficker E, Kuryshev YA, Dennis AT, Objero-Paz C, Wang L, Hawryluk P, Wible BA, and Brown AM (2004) Mechanism of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44.
15. Franco MA, Barbosa AC, Rath S, and Dorea JG (1995) Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg 52:435-437.
16. Frezard F, Demicheli C, Ferreira CS, and Costa MA (2001) Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother 45:913-916.
17. Goodwin LG and Page JE (1943) A study of the excretion of organic antimonials using a polarographic procedure. Biochem J 37:198-209.
18. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, and Bryceson ADM (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment and a proposed research and development agenda. Lancet Infect Dis 2:494-501.
19. Herwaldt BL (1999) Leishmaniasis. Lancet 354:1191-1199.
20. Jaser MA, El-Yazigi A, and Croft SL (1995) Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res (NY) 12:113-116.
21. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, et al. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316-323.
22. Lecureur V, Lagadic-Gossmann D, and Fardel O (2002) Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. Int J Oncol 20:1071-1076.
23. Liu SX, Athar M, Lippai I, Waldren C, and Hei TK (2001) Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98:1643-1648.
24. Miekeley N, Mortari SR, and Schubach AO (2002) Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Anal Bioanal Chem 372:495-502.
25. Miller WH, Schipper HM, Lee JS, Singer J, and Waxman S (2002) Mechanism of action of arsenic trioxide. Cancer Res 62:3893-3903.
26. Mueller S, Miller WH, and Dejean A (1998) Trivalent antimonials induce degradation of the PML-RARα oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92:4308-4316.
27. Murray HW, Pepin J, Nutman TB, Hoffman SL, and Mahmoud AA (2000) Tropical medicine. BMJ 320:490-494.
28. Ortega-Carnicer J, Alcazar R, De la Torre M, and Benezet J (1997) Pentavalent antimonial-induced torsade de pointes. J Electrocardiol 30:143-145.
29. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, and Yi T (2002) Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 1:1255-1264.
30. Rees PH, Keating MI, Kager PA, and Hockmeyer WT (1980) Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2:226-229.
31. Roberts WL, Berman JD, and Rainey PM (1995) In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 39:1234-1239.
32. Schulert AR, Rassoul AA, Mansour M, Girgis N, McConnell E, and Farid Z (1966) Biological disposition of antibilharzial antimony drugs. II. Antimony fate and uptake by Schistosoma haematobium eggs in man. Exp Parasitol 18:397-402.
33. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
34. v1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19-31.
35. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, and Keating MT (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 102:8089-8096.
36. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, and Singh VP (1998) A cluster of cases of severe cardiotoxicity among Kala-Azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 59:139-143.
37. + channels by reactive oxygen species. Proc Natl Acad Sci USA 94:11698-11703.
38. Thakur CP (1998) Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 351:1928-1929.
39. Tirmenstein MA, Plews PI, Walker CV, Woolery MD, Wey HE, and Toraason MA (1995) Antimony-induced oxidative stress and toxicity in cultured cardiac myocytes. Toxicol Appl Pharmacol 130:41-47.
40. Wyllie S, Cunningham ML, and Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279:39925-39932.
41. Zhou Z, Gong Q, Epstein ML, and January CT (1998) HERG channel dysfunction in human long QT syndrome. J Biol Chem 273:21061-21066.